Fostemsavir vs YASO GEL

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV gp120 · full HIV pipeline

Fostemsavir · Rukobia

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Partial signal

NCT02362503 · Phase 3 · active, not recruiting

The randomized, double-blind comparison against placebo was statistically clear (p<0.0001), but the primary endpoint was the short-term change in viral load at Day 8, a pharmacodynamic measure of antiviral activity rather than sustained viral suppression. Only 270 participants entered the randomized comparison, and the rest of the study, including the non-randomized cohort and the long-term follow-up, was open label.

Next expected readout: January 2027 · NCT07053384 (registry estimate)

Reported efficacy

Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007) (met)

Result source: NCT02362503

YASO GEL

Developed by Yaso Therapeutics

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFostemsavirYASO GEL
HIV-1 RNA below 50 copies/mL (week 48)72% vs 75%vs ATV/r1200 mg QD · wk 24 · n 50NCT01384734
11 other results
  • 69% vs 75% 800 mg BID · wk 24 · n 49 · Phase 2 · primary NCT01384734
  • 76% vs 75% 600 mg QD · wk 24 · n 51 · Phase 2 · primary NCT01384734
  • 80% vs 75% 400 mg BID · wk 24 · n 50 · Phase 2 · primary NCT01384734
  • 58% vs 57% 1200 mg QD · wk 96 · n 50 · Phase 2 · secondary NCT01384734
  • 68% vs 71% 1200 mg QD · wk 48 · n 50 · Phase 2 · secondary NCT01384734
  • 49% vs 57% 800 mg BID · wk 96 · n 49 · Phase 2 · secondary NCT01384734
  • 61% vs 71% 800 mg BID · wk 48 · n 49 · Phase 2 · secondary NCT01384734
  • 63% vs 57% 600 mg QD · wk 96 · n 51 · Phase 2 · secondary NCT01384734
  • 69% vs 71% 600 mg QD · wk 48 · n 51 · Phase 2 · secondary NCT01384734
  • 78% vs 57% 400 mg BID · wk 96 · n 50 · Phase 2 · secondary NCT01384734
  • 82% vs 71% 400 mg BID · wk 48 · n 50 · Phase 2 · secondary NCT01384734
—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT02362503—Not reported
CD4 count, change (week 48)211.7 vs 250.1vs ATV/r1200 mg QD · wk 96 · n 50NCT01384734
11 other results
  • 155.4 vs 178.7 1200 mg QD · wk 48 · n 50 · Phase 2 · secondary NCT01384734
  • 124.5 vs 119.4 1200 mg QD · wk 24 · n 50 · Phase 2 · secondary NCT01384734
  • 210.8 vs 250.1 800 mg BID · wk 96 · n 49 · Phase 2 · secondary NCT01384734
  • 158.7 vs 178.7 800 mg BID · wk 48 · n 49 · Phase 2 · secondary NCT01384734
  • 111 vs 119.4 800 mg BID · wk 24 · n 49 · Phase 2 · secondary NCT01384734
  • 175.7 vs 250.1 600 mg QD · wk 96 · n 51 · Phase 2 · secondary NCT01384734
  • 140.5 vs 178.7 600 mg QD · wk 48 · n 51 · Phase 2 · secondary NCT01384734
  • 109.5 vs 119.4 600 mg QD · wk 24 · n 51 · Phase 2 · secondary NCT01384734
  • 264.6 vs 250.1 400 mg BID · wk 96 · n 50 · Phase 2 · secondary NCT01384734
  • 199.1 vs 178.7 400 mg BID · wk 48 · n 50 · Phase 2 · secondary NCT01384734
  • 134.3 vs 119.4 400 mg BID · wk 24 · n 50 · Phase 2 · secondary NCT01384734
—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Fostemsavir
72% vs 75%vs ATV/r1200 mg QD · wk 24 · n 50NCT01384734
11 other results
  • 69% vs 75% 800 mg BID · wk 24 · n 49 · Phase 2 · primary NCT01384734
  • 76% vs 75% 600 mg QD · wk 24 · n 51 · Phase 2 · primary NCT01384734
  • 80% vs 75% 400 mg BID · wk 24 · n 50 · Phase 2 · primary NCT01384734
  • 58% vs 57% 1200 mg QD · wk 96 · n 50 · Phase 2 · secondary NCT01384734
  • 68% vs 71% 1200 mg QD · wk 48 · n 50 · Phase 2 · secondary NCT01384734
  • 49% vs 57% 800 mg BID · wk 96 · n 49 · Phase 2 · secondary NCT01384734
  • 61% vs 71% 800 mg BID · wk 48 · n 49 · Phase 2 · secondary NCT01384734
  • 63% vs 57% 600 mg QD · wk 96 · n 51 · Phase 2 · secondary NCT01384734
  • 69% vs 71% 600 mg QD · wk 48 · n 51 · Phase 2 · secondary NCT01384734
  • 78% vs 57% 400 mg BID · wk 96 · n 50 · Phase 2 · secondary NCT01384734
  • 82% vs 71% 400 mg BID · wk 48 · n 50 · Phase 2 · secondary NCT01384734
YASO GEL
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Fostemsavir
—Trial running · NCT02362503
YASO GEL
—Not reported

CD4 count, change (week 48)

Fostemsavir
211.7 vs 250.1vs ATV/r1200 mg QD · wk 96 · n 50NCT01384734
11 other results
  • 155.4 vs 178.7 1200 mg QD · wk 48 · n 50 · Phase 2 · secondary NCT01384734
  • 124.5 vs 119.4 1200 mg QD · wk 24 · n 50 · Phase 2 · secondary NCT01384734
  • 210.8 vs 250.1 800 mg BID · wk 96 · n 49 · Phase 2 · secondary NCT01384734
  • 158.7 vs 178.7 800 mg BID · wk 48 · n 49 · Phase 2 · secondary NCT01384734
  • 111 vs 119.4 800 mg BID · wk 24 · n 49 · Phase 2 · secondary NCT01384734
  • 175.7 vs 250.1 600 mg QD · wk 96 · n 51 · Phase 2 · secondary NCT01384734
  • 140.5 vs 178.7 600 mg QD · wk 48 · n 51 · Phase 2 · secondary NCT01384734
  • 109.5 vs 119.4 600 mg QD · wk 24 · n 51 · Phase 2 · secondary NCT01384734
  • 264.6 vs 250.1 400 mg BID · wk 96 · n 50 · Phase 2 · secondary NCT01384734
  • 199.1 vs 178.7 400 mg BID · wk 48 · n 50 · Phase 2 · secondary NCT01384734
  • 134.3 vs 119.4 400 mg BID · wk 24 · n 50 · Phase 2 · secondary NCT01384734
YASO GEL
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

YASO GEL: no structured comparison results are available for HIV.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fostemsavir: 4 of 4 rows · YASO GEL: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFostemsavir
Dropout rate
—600 mg BIDa
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
show 10 more results
2%600 mg BID
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
56%1200 mg QD
NCT01384734 · Phase 2 · combination
49%800 mg BID
NCT01384734 · Phase 2 · combination
45.1%600 mg QD
NCT01384734 · Phase 2 · combination
34%400 mg BID
NCT01384734 · Phase 2 · combination
0%1200 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence
0%1200 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0%1200 mg Q12H + RTV 100 mg QAM
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
10%1200 mg QHS + RTV 100 mg QHS
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
10%600 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—600 mg BIDa
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
show 10 more results
1%600 mg BID
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
4%1200 mg QD
NCT01384734 · Phase 2 · combination
6.1%800 mg BID
NCT01384734 · Phase 2 · combination
0%600 mg QD
NCT01384734 · Phase 2 · combination
0%400 mg BID
NCT01384734 · Phase 2 · combination
—1200 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence
—1200 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
—1200 mg Q12H + RTV 100 mg QAM
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
—1200 mg QHS + RTV 100 mg QHS
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
—600 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
48.5%600 mg BIDa
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
show 10 more results
2%600 mg BID
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
—1200 mg QD
NCT01384734 · Phase 2 · combination
—800 mg BID
NCT01384734 · Phase 2 · combination
—600 mg QD
NCT01384734 · Phase 2 · combination
—400 mg BID
NCT01384734 · Phase 2 · combination
0%1200 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence
0%1200 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0%1200 mg Q12H + RTV 100 mg QAM
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0%1200 mg QHS + RTV 100 mg QHS
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0%600 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
600 mg BIDa
diarrhoea 25.3% (placebo 4.3%)
nausea 21.2% (placebo 5.8%)
nasopharyngitis 19.2% (placebo 0%)
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
show 6 more results
600 mg BID
nausea 6.9% (placebo 5.8%)
diarrhoea 3.9% (placebo 4.3%)
headache 3% (placebo 7.2%)
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
1200 mg Q12H
headache 40%
micturition urgency 30%
diarrhoea 20%
NCT01009814 · Phase 2 · registry result, not featured evidence
1200 mg Q12H + RTV 100 mg Q12H
headache 40%
nasopharyngitis 30%
rash 20%
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
1200 mg Q12H + RTV 100 mg QAM
headache 30%
erythema 20%
nasopharyngitis 20%
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
1200 mg QHS + RTV 100 mg QHS
headache 30%
discomfort 10%
influenza like illness 10%
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
600 mg Q12H + RTV 100 mg Q12H
headache 40%
rash 20%
asthenia 10%
NCT01009814 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 9 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fostemsavir

HIV-1 RNA -0.791 vs -0.166 placebo log @ 1wk600 mg BID
absolute change · log
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
CD4+ 18.5 vs 18.9 placebo cells/uL @ 1wk600 mg BID
absolute change · cells/uL
NCT02362503 · Phase 3 · monotherapy · HIV · phase 3
show 12 more results
124.5 vs 119.4 ATV/r cells/uL @ 24wk1200 mg QD
NCT01384734 · Phase 2 · combination
155.4 vs 178.7 ATV/r cells/uL @ 48wk1200 mg QD
NCT01384734 · Phase 2 · combination
211.7 vs 250.1 ATV/r cells/uL @ 96wk1200 mg QD
NCT01384734 · Phase 2 · combination
111 vs 119.4 ATV/r cells/uL @ 24wk800 mg BID
NCT01384734 · Phase 2 · combination
158.7 vs 178.7 ATV/r cells/uL @ 48wk800 mg BID
NCT01384734 · Phase 2 · combination
210.8 vs 250.1 ATV/r cells/uL @ 96wk800 mg BID
NCT01384734 · Phase 2 · combination
109.5 vs 119.4 ATV/r cells/uL @ 24wk600 mg QD
NCT01384734 · Phase 2 · combination
140.5 vs 178.7 ATV/r cells/uL @ 48wk600 mg QD
NCT01384734 · Phase 2 · combination
175.7 vs 250.1 ATV/r cells/uL @ 96wk600 mg QD
NCT01384734 · Phase 2 · combination
134.3 vs 119.4 ATV/r cells/uL @ 24wk400 mg BID
NCT01384734 · Phase 2 · combination
199.1 vs 178.7 ATV/r cells/uL @ 48wk400 mg BID
NCT01384734 · Phase 2 · combination
264.6 vs 250.1 ATV/r cells/uL @ 96wk400 mg BID
NCT01384734 · Phase 2 · combination
HIV-1 RNA Less Than 50 Copies 72% (n=50) vs 75% (n=51) ATV/r @ 24wk1200 mg QD
responder rate · % of participants
NCT01384734 · Phase 2 · combination
show 11 more results
68% (n=50) vs 71% (n=51) ATV/r @ 48wk1200 mg QD
NCT01384734 · Phase 2 · combination
58% (n=50) vs 57% (n=51) ATV/r @ 96wk1200 mg QD
NCT01384734 · Phase 2 · combination
69% (n=49) vs 75% (n=51) ATV/r @ 24wk800 mg BID
NCT01384734 · Phase 2 · combination
61% (n=49) vs 71% (n=51) ATV/r @ 48wk800 mg BID
NCT01384734 · Phase 2 · combination
49% (n=49) vs 57% (n=51) ATV/r @ 96wk800 mg BID
NCT01384734 · Phase 2 · combination
76% (n=51) vs 75% (n=51) ATV/r @ 24wk600 mg QD
NCT01384734 · Phase 2 · combination
69% (n=51) vs 71% (n=51) ATV/r @ 48wk600 mg QD
NCT01384734 · Phase 2 · combination
63% (n=51) vs 57% (n=51) ATV/r @ 96wk600 mg QD
NCT01384734 · Phase 2 · combination
80% (n=50) vs 75% (n=51) ATV/r @ 24wk400 mg BID
NCT01384734 · Phase 2 · combination
82% (n=50) vs 71% (n=51) ATV/r @ 48wk400 mg BID
NCT01384734 · Phase 2 · combination
78% (n=50) vs 57% (n=51) ATV/r @ 96wk400 mg BID
NCT01384734 · Phase 2 · combination
HIV-1 RNA 0.126 log @ 0.29wk1200 mg QD
absolute change · log
No placebo or comparator arm
NCT01384734 · Phase 2 · combination
show 24 more results
-0.767 log @ 0.71wk1200 mg QD
NCT01384734 · Phase 2 · combination
-1.053 log @ 0.86wk1200 mg QD
NCT01384734 · Phase 2 · combination
-1.198 log @ 1wk1200 mg QD
NCT01384734 · Phase 2 · combination
-1.47 log @ 1.14wk1200 mg QD
NCT01384734 · Phase 2 · combination
-1.2532 log @ 1.285714wk1200 mg QHS + RTV 100 mg QHS
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
-1.2381 log @ 1.285714wk1200 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
-1.1888 log @ 1.285714wk1200 mg Q12H + RTV 100 mg QAM
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
-0.876 log @ 1.285714wk1200 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence
0.149 log @ 0.29wk800 mg BID
NCT01384734 · Phase 2 · combination
-0.811 log @ 0.71wk800 mg BID
NCT01384734 · Phase 2 · combination
-1.082 log @ 0.86wk800 mg BID
NCT01384734 · Phase 2 · combination
-1.443 log @ 1wk800 mg BID
NCT01384734 · Phase 2 · combination
-1.372 log @ 1.14wk800 mg BID
NCT01384734 · Phase 2 · combination
0.126 log @ 0.29wk600 mg QD
NCT01384734 · Phase 2 · combination
-0.593 log @ 0.71wk600 mg QD
NCT01384734 · Phase 2 · combination
-0.822 log @ 0.86wk600 mg QD
NCT01384734 · Phase 2 · combination
-1.086 log @ 1wk600 mg QD
NCT01384734 · Phase 2 · combination
-1.218 log @ 1.14wk600 mg QD
NCT01384734 · Phase 2 · combination
-1.3445 log @ 1.285714wk600 mg Q12H + RTV 100 mg Q12H
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0.22 log @ 0.29wk400 mg BID
NCT01384734 · Phase 2 · combination
-0.34 log @ 0.71wk400 mg BID
NCT01384734 · Phase 2 · combination
-0.53 log @ 0.86wk400 mg BID
NCT01384734 · Phase 2 · combination
-0.556 log @ 1wk400 mg BID
NCT01384734 · Phase 2 · combination
-0.691 log @ 1.14wk400 mg BID
NCT01384734 · Phase 2 · combination
HIV-1 RNA Less Than 50 Copies 11% (n=9) @ 1.14wk1200 mg QD
responder rate · % of participants
No placebo or comparator arm
NCT01384734 · Phase 2 · combination
show 3 more results
0% (n=4) @ 1.14wk800 mg BID
NCT01384734 · Phase 2 · combination
0% (n=9) @ 1.14wk600 mg QD
NCT01384734 · Phase 2 · combination
0% (n=6) @ 1.14wk400 mg BID
NCT01384734 · Phase 2 · combination
CD4+ 93.4 cells/uL @ 1.14wk1200 mg QHS + RTV 100 mg QHS
absolute change · cells/uL
No placebo or comparator arm
CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
show 4 more results
109.8 cells/uL @ 1.14wk1200 mg Q12H + RTV 100 mg Q12H
CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
38.5 cells/uL @ 1.14wk1200 mg Q12H + RTV 100 mg QAM
CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
32 cells/uL @ 1.14wk1200 mg Q12H
CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence
114.2 cells/uL @ 1.14wk600 mg Q12H + RTV 100 mg Q12H
CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
CD4+ -6.1 cells/uL @ 2.14wk1200 mg QHS + RTV 100 mg QHS
absolute change · cells/uL
No placebo or comparator arm
CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
show 4 more results
117.6 cells/uL @ 2.14wk1200 mg Q12H + RTV 100 mg Q12H
CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
44.6 cells/uL @ 2.14wk1200 mg Q12H + RTV 100 mg QAM
CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
10.4 cells/uL @ 2.14wk1200 mg Q12H
CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence
58.4 cells/uL @ 2.14wk600 mg Q12H + RTV 100 mg Q12H
CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
CD4+ -50.3 cells/uL @ 7.14wk1200 mg QHS + RTV 100 mg QHS
absolute change · cells/uL
No placebo or comparator arm
CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
show 4 more results
71.1 cells/uL @ 7.14wk1200 mg Q12H + RTV 100 mg Q12H
CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
-48.4 cells/uL @ 7.14wk1200 mg Q12H + RTV 100 mg QAM
CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
-19.2 cells/uL @ 7.14wk1200 mg Q12H
CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence
22 cells/uL @ 7.14wk600 mg Q12H + RTV 100 mg Q12H
CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
CD4+ 1.2% (n=9) @ 1.14wk1200 mg QHS + RTV 100 mg QHS
absolute change · percentage points
No placebo or comparator arm
Percent CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
show 4 more results
0.6% (n=10) @ 1.14wk1200 mg Q12H + RTV 100 mg Q12H
Percent CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0.1% (n=10) @ 1.14wk1200 mg Q12H + RTV 100 mg QAM
Percent CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
1.4% (n=10) @ 1.14wk1200 mg Q12H
Percent CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence
-1% (n=9) @ 1.14wk600 mg Q12H + RTV 100 mg Q12H
Percent CD4+, Day 8, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
CD4+ 1.2% (n=9) @ 2.14wk1200 mg QHS + RTV 100 mg QHS
absolute change · percentage points
No placebo or comparator arm
Percent CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
show 4 more results
1.4% (n=10) @ 2.14wk1200 mg Q12H + RTV 100 mg Q12H
Percent CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
2.4% (n=10) @ 2.14wk1200 mg Q12H + RTV 100 mg QAM
Percent CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0.9% (n=10) @ 2.14wk1200 mg Q12H
Percent CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence
1.6% (n=9) @ 2.14wk600 mg Q12H + RTV 100 mg Q12H
Percent CD4+, Day 15, n=9, 9, 10, 10, 10
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
CD4+ 1.1% (n=9) @ 7.14wk1200 mg QHS + RTV 100 mg QHS
absolute change · percentage points
No placebo or comparator arm
Percent CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
show 4 more results
0.3% (n=10) @ 7.14wk1200 mg Q12H + RTV 100 mg Q12H
Percent CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
-1.7% (n=10) @ 7.14wk1200 mg Q12H + RTV 100 mg QAM
Percent CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination
0.6% (n=10) @ 7.14wk1200 mg Q12H
Percent CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence
1.4% (n=9) @ 7.14wk600 mg Q12H + RTV 100 mg Q12H
Percent CD4+, Day 50, n=9, 9, 10, 10, 9
NCT01009814 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fostemsavir's landscape · YASO GEL's landscape